First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In an interim analysis of a trial involving 296 patients with
ALK
-positive non–small-cell lung cancer, lorlatinib, an anaplastic lymphoma kinase inhibitor, was superior to crizotinib in response (in 76% vs. 58%), 12-month progression-free survival (78% vs. 39%), and intracranial disease response (82% vs. 23%). Altered lipid levels were the m...
Alternative Titles
Full title
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2462161813
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2462161813
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2027187
